INTRODUCTION {#s1}
============

Atopic diseases which include atopic dermatitis(AD), allergic rhinitis(AR), and asthma(AA) are closely related. Allergic rhinitis is often present in asthmatics and the incidence of asthma development in individuals suffering from allergic rhinitis is five times of those bearing no allergic rhinitis \[[@R1]\]. It has been reported that allergic symptoms could start with atopic dermatitis in infancy followed by allergic rhinitis and asthma later in life \[[@R2]\]. In addition, development of atopic diseases is attributed to genetic and environmental factors in a great extent \[[@R3]\].

It has been proposed that TAP gene may be responsible for atopic disease susceptibility. Polymorphisms in TAP1 may affect antigen recognition and presentation, potentially resulting in low expression or entirely absence of MHC-I at the cell surface, which could ultimately lead to an adverse immune response \[[@R4]\]. Studies on the polymorphisms of the TAP1 gene in several human leukocyte antigen (HLA)-associated diseases such as atopic dermatitis, asthma, rhinitis \[[@R5]--[@R14]\] found that rs1057141 and rs1135216 as the most common single nucleotide polymorphisms. Currently, controversial opinions are presented for the relationships between TAP1 gene polymorphisms and atopic diseases. This may be resulted from the moderate sample size of the previous studies which could not provide inclusive findings. Therefore, to gain a more comprehensive insight of the association of TAP1 polymorphisms with the development of atopic diseases, our study performed a set of meta-analysis by utilizing pooled data from selected studies on the association of two TAP1 polymorphisms rs1057141 and rs1135216 and atopic diseases.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

By following literature selection process as illustrated in Figure [1](#F1){ref-type="fig"}, 138 studies were identified from PubMed, Embase and Web of Science databases (PubMed: 20, Embase: 30, Web of Science: 88). Subsequently, 126 articles were excluded due to duplication (n=24) or without relation to this topic (n=102). Following detailed evaluation of the remaining twelve studies, four studies were excluded with one being lack of relation to rs1057141 or rs1135216 polymorphism \[[@R15]\], one not being a case-control study \[[@R16]\], and two lack of enough pertinent data \[[@R8], [@R14]\]. A total of 8 articles, with 7 published in English and 1 in Chinese, were included for qualitative synthesis based on the inclusion and exclusion criteria \[[@R5]--[@R7], [@R9]--[@R13]\]. One of the articles was further separated into three studies because it examined different atopic types \[[@R7]\] (Table [1](#T1){ref-type="table"}). Therefore, in total, data from 10 case-control studies, amounting to 661 cases and 876 controls for rs1057141 and 668 cases and 876 controls for rs1135216, were pooled into the meta-analysis. Of these, there were 4 studies of atopic dermatitis, 4 studies of allergic rhinitis, and 2 studies of asthma. Characteristics of studies investigating the relationship between rs1057141 and rs1135216 single nucleotide polymorphism and atopic diseases are summarized in Table [1](#T1){ref-type="table"}. For all the studies, genomic DNA isolated from blood samples was used for genotyping, for which PCR-ARMS assay were used in five studies; PCR-RFLP method were applied in three studies, PCR-SSCP assay was used in one study, and SNaPshot system assay was used in one study.

![Workflow for literature selection](oncotarget-09-1553-g001){#F1}

###### Characteristics of studies in the meta-analysis

  Author     year   Location   Ethnicity   Atopic type   Genotyping   TAP1 rs1057141 Case/Control   TAP1 rs1135216 Case/Control   NOS                                             
  ---------- ------ ---------- ----------- ------------- ------------ ----------------------------- ----------------------------- ------ ------- --------- ------- ------ ------- ----
  Chen       2012   China      Asia        AR            SNaPshot     96/99                         50/45                         4/6    0.756   104/107   43/41   3/2    0.379   11
  Kim        2007   Korea      Asia        AR            ARMS         82/54                         26/53                         2/0    0.001   76/55     30/50   4/2    0.014   8
  Hang       2003   Taiwan     Asia        AA            RFLP         58/25                         45/15                         6/3    0.719   76/37     39/6    1/0    0.623   10
  Takeuchi   2002   Japan      Asia        AR            ARMS         50/50                         9/11                          1/1    0.666   46/42     12/19   2/1    0.482   11
  Lee        2001   Korea      Asia        AD            SSCP         34/113                        16/60                         3/11   0.427   36/125    15/55   2/4    0.469   9
  Ismail     1997   Tunisia    Africa      AA            ARMS         31/65                         15/14                         2/2    0.261   19/62     6/16    23/3   0.159   10
  Ismail     1997   Tunisia    Africa      AR            ARMS         24/65                         21/14                         0/2    0.261   19/62     15/16   11/3   0.159   10
  Ismail     1997   Tunisia    Africa      AD            ARMS         12/65                         6/14                          2/2    0.261   8/62      9/16    3/3    0.159   10
  Kuwata     1995   Japan      Asia        AD            RFLP         27/38                         9/12                          1/2    0.413   28/39     8/11    1/2    0.302   8
  Kuwata     1994   Japan      Asia        AD            RFLP         21/28                         8/7                           0/0    0.511   26/22     3/13    0/0    0.177   8

AD, atopic dermatitis; AR, allergic rhinitis; AA, asthma; ARMS, amplification refractory mutation system; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformation polymorphism; HWE, Hardy-Weinberg Equilibrium; NOS, Newcastle-Ottawa Scale.

Meta-analysis results

### TAP1 rs1057141 polymorphism and atopic diseases susceptibility {#s2_1_1}

The summary of meta-analysis for TAP1 rs1057141 polymorphism with atopic diseases was demonstrated in Table [2](#T2){ref-type="table"}. Overall, significant association was not identified in any genetic model. Besides, it was revealed that significant heterogeneity was present in allelic, dominant, heterozygous genetic models (Table [2](#T2){ref-type="table"}). Interestingly, when stratified by ethnicity, heterogeneity disappeared in Asians (I^2^ = 22.1%, *P*~h~ = 0.260) and Africans (I^2^ = 0%, *P*~h~ = 0.852) in allelic comparisons (Figure [2](#F2){ref-type="fig"}). In African population, increased risk of atopic disease was found in the allelic (odds ratio (OR)= 2.29, 95% CI (confidence interval) 1.49-3.52, *P* \< 0.001), dominant (OR = 2.79, 95% CI 1.70-4.59, *P* \< 0.001) and heterozygous (OR = 2.88, 95% CI 1.72-4.85, *P* \< 0.001) model (Table [2](#T2){ref-type="table"}). Additionally, subgroup analysis was conducted by dividing the whole population into three subgroups by atopic types, which include AA, AD, AR groups. No significant association was identified in any genetic models (Table [2](#T2){ref-type="table"}).

###### Analysis of the effect of TAP1 rs1057141 on the risk of atopic diseases

  Genetic model                  Population   Studies   Statistics            Heterogeneity   Publication bias                              
  ------------------------------ ------------ --------- --------------------- --------------- ------------------ ------- ------ --- ------- -------
  **Allele (G vs. A)**           Overall      10        1.16(0.83--1.63)      0.88            0.378              0.005   62.1   R   0.283   0.160
                                 AR           4         0.98(0.52--1.86)      0.05            0.963              0.002   79.4   R   1.000   0.699
                                 AA           2         1.38(0.88--2.16)      1.41            0.158              0.204   38.0   F   1.000   NA
                                 AD           4         1.26(0.77-2.06)       0.92            0.359              0.198   35.7   F   0.308   0.388
                                 Asian        7         0.87(0.69-1.08)       1.29            0.196              0.260   22.1   F   0.764   0.591
                                 African      3         **2.29(1.49-3.52)**   3.79            0.000              0.852   0.0    F   1.000   0.565
  **Dominant (GG+AG vs. AA)**    Overall      10        1.22(0.78--1.90)      0.87            0.386              0.000   70.7   R   0.283   0.185
                                 AR           4         1.01(0.41--2.50)      0.02            0.986              0.000   86.7   R   1.000   0.697
                                 AA           2         1.60(0.89--2.88)      1.57            0.116              0.273   16.6   F   1.000   NA
                                 AD           4         1.23(0.76-1.98)       0.83            0.407              0.325   13.5   F   0.308   0.254
                                 Asian        7         0.86(0.58-1.28)       0.73            0.466              0.051   52.1   R   1.000   0.590
                                 African      3         **2.79(1.70-4.59)**   4.04            0.000              0.721   0.0    F   1.000   0.937
  **Recessive (GG vs. AG+AA)**   Overall      10        1.03(0.57--1.86)      0.09            0.926              0.814   0.0    F   0.466   0.378
                                 AR           4         0.87(0.34--2.26)      0.28            0.778              0.617   0.0    F   1.000   0.578
                                 AA           2         1.02(0.31--3.32)      0.03            0.972              0.526   0.0    F   1.000   NA
                                 AD           4         1.24(0.47--3.28)      0.43            0.667              0.391   0.0    F   1.000   0.815
                                 Asian        7         0.91(0.46-1.78)       0.29            0.773              0.909   0.0    F   0.260   0.187
                                 African      3         1.58(0.47-5.31)       0.74            0.457              0.383   0.0    F   1.000   0.339
  **Homozygous (GG vs. AA)**     Overall      10        1.08(0.59--1.96)      0.24            0.812              0.834   0.0    F   0.602   0.352
                                 AR           4         0.88(0.33--2.35)      0.25            0.801              0.809   0.0    F   0.734   0.474
                                 AA           2         1.17(0.35--3.86)      0.25            0.800              0.483   0.0    F   1.000   NA
                                 AD           4         1.25(0.47--3.34)      0.45            0.655              0.303   16.4   F   1.000   0.783
                                 Asian        7         0.89(0.45-1.78)       0.32            0.750              0.970   0.0    F   0.133   0.196
                                 African      3         2.07(0.60-1.96)       1.16            0.247              0.452   0.0    F   1.000   0.385
  **Heterozygous (AG vs. AA)**   Overall      10        0.76(0.76--1.97)      0.85            0.398              0.000   72.2   R   0.283   0.213
                                 AR           4         1.03(0.38--2.80)      0.06            0.949              0.000   88.4   R   1.000   0.696
                                 AA           2         1.65(0.94--2.89)      1.75            0.080              0.338   0.0    F   1.000   NA
                                 AD           4         1.17(0.74--1.85)      0.68            0.500              0.514   0.0    F   0.308   0.148
                                 Asian        7         0.87(0.56-1.36)       0.60            0.549              0.025   58.4   R   1.000   0.582
                                 African      3         **2.88(1.72-4.85)**   4.00            0.000              0.565   0.0    F   1.000   0.696

![Subgroup analysis of the relationship between TAP1 rs1057141 polymorphism and atopic diseases stratified by the ethnicity of study population\
I^2^ and P~heterogeneity~ for the outcomes of the allelic comparison in Asians (I^2^=22.1%, *P*~h~=0.260) and Africans (I^2^ = 0, *P*~h~= 0.852).](oncotarget-09-1553-g002){#F2}

AD, atopic dermatitis; AR, allergic rhinitis; AA, asthma; OR, odds ratio; CI, confidence interval; NA, not applicable; Bold values are statistically significant (*P* \< 0.05).

### TAP1 rs1135216 polymorphism and atopic diseases susceptibility {#s2_1_2}

The results of associations between rs1135216 polymorphism and the risk of atopic diseases were shown in Table [3](#T3){ref-type="table"}. A significant increase in the risk of atopic diseases was observed in recessive comparison (OR = 4.71, 95% CI 2.75-8.06, *P* \< 0.001) and homozygote comparison (OR = 3.68, 95% CI 1.53-8.89, *P* \< 0.001) in overall populations (Figure [3](#F3){ref-type="fig"}).

###### Analysis of the effect of TAP1 rs1135216 on the risk of atopic diseases

  Genetic model              Population   Studies   Statistics              Heterogeneity   Publication bias                              
  -------------------------- ------------ --------- ----------------------- --------------- ------------------ ------- ------ --- ------- -------
  Allele (G vs. A)           Overall      10        1.52(0.83-2.78)         1.36            0.174              0.000   88.2   R   1.000   0.819
                             AR           4         1.22(0.54-2.74)         0.49            0.628              0.000   88.8   R   1.000   0.642
                             AA           2         **4.92(1.90-12.69)**    3.29            0.001              0.077   68.1   R   1.000   NA
                             AD           4         1.07(0.42-2.70)         0.14            0.885              0.002   79.9   R   0.734   0.604
                             Asian        7         0.91(0.62-1.35)         0.46            0.648              0.027   57.8   R   0.764   0.894
                             African      3         **5.33(3.67-7.75)**     8.77            0.000              0.318   12.6   F   0.296   0.535
  Dominant (GG+AG vs. AA)    Overall      10        1.39(0.76-2.55)         1.07            0.284              0.000   83.8   R   1.000   0.519
                             AR           4         1.08(0.45-2.59)         0.18            0.859              0.000   86.6   R   1.000   0.617
                             AA           2         **4.10(2.24-7.52)**     4.56            0.000              0.489   0.0    F   1.000   NA
                             AD           4         1.04(0.36-3.01)         0.08            0.937              0.003   79.0   R   1.000   0.800
                             Asian        7         0.84(0.51-1.39)         0.68            0.500              0.006   67.1   R   0.764   0.881
                             African      3         **4.76(2.93-7.73)**     6.29            0.000              0.979   0.0    F   1.000   0.832
  Recessive (GG vs. AG+AA)   Overall      10        **4.71(2.75-8.06)**     5.65            0.000              0.078   43.5   F   0.029   0.016
                             AR           4         **3.46(1.51-7.93)**     2.94            0.003              0.381   2.3    F   0.734   0.252
                             AA           2         7.54(0.41-137.37)       1.36            0.173              0.084   66.5   R   1.000   NA
                             AD           4         2.02(0.70-5.81)         1.31            0.191              0.434   0.0    F   0.296   0.372
                             Asian        7         1.55(0.67-3.56)         1.03            0.304              0.987   0.0    F   0.133   0.291
                             African      3         **12.15(5.54-26.62)**   6.24            0.000              0.267   24.3   F   0.296   0.386
  Homozygous (GG vs. AA)     Overall      10        **3.68(1.53-8.89)**     2.90            0.004              0.038   50.9   R   0.251   0.026
                             AR           4         **3.52(1.53-8.10)**     2.96            0.003              0.163   41.4   F   1.000   0.269
                             AA           2         9.03(0.63-130.17)       1.62            0.106              0.110   60.8   R   1.000   NA
                             AD           4         2.28(0.79-6.60)         1.51            0.130              0.240   29.8   F   1.000   0.526
                             Asian        7         1.43(0.62-3.32)         0.84            0.400              0.995   0.0    F   0.707   0.534
                             African      3         **15.85(6.96-36.08)**   6.58            0.000              0.532   0.0    F   0.296   0.375
  Heterozygous (AG vs. AA)   Overall      10        1.11(0.66-1.85)         0.38            0.702              0.000   73.9   R   0.474   0.486
                             AR           4         0.92(0.43-1.97)         0.21            0.837              0.002   80.4   R   0.734   0.670
                             AA           2         **2.18(1.11-4.31)**     2.25            0.024              0.190   41.8   F   1.000   NA
                             AD           4         1.00(0.36-2.80)         0.01            0.996              0.006   75.7   R   1.000   0.845
                             Asian        7         0.81(0.48-1.36)         0.80            0.425              0.004   68.3   R   0.764   0.899
                             African      3         **2.54(1.44-4.46)**     3.24            0.001              0.235   30.9   F   1.000   0.876

![Overall meta-analysis of the relationship between TAP1 rs1135216 polymorphism and atopic diseases risk\
**A**. Recessive model (GG *vs*. AA+AG); **B**. Homozygote model (GG *vs*. AA).](oncotarget-09-1553-g003){#F3}

From subgroup analysis by ethnicity, it demonstrated a significant association of TAP1 rs1135216 polymorphism and atopic diseases in Africans in all five genetic models (G versus A: OR = 5.33, 95% CI 3.67-7.75, *P* \< 0.001; AG/GG versus AA: OR = 4.76, 95% CI 2.93-7.73, *P* \< 0.001; GG versus AG/AA: OR = 12.15, 95% CI 5.54-26.62, *P* \< 0.001; GG versus AA: OR = 15.85, 95% CI 6.96-36.08, *P* \< 0.001; AG versus AA: OR = 2.54, 95% CI 1.44-4.46, *P* = 0.001) but not in Asians (Table [3](#T3){ref-type="table"}). Interestingly, when stratified by ethnicity, heterogeneity disappeared in Asians (I^2^ = 0%, P~h~ = 0.995) and Africans (I^2^ = 0%, P~h~ = 0.532) in homozygous comparison (Figure [4](#F4){ref-type="fig"}). Subgroup analysis by atopic types indicated a significant association in AA in the allele (OR = 4.92, 95% CI 1.90-12.69, *P* = 0.001), dominant (OR = 4.10, 95% CI 2.24-7.52, *P* \< 0.001) and heterozygous (OR = 2.18, 95% CI 1.11-4.31, *P* = 0.024) models and AR in the recessive (OR = 3.46, 95% CI 1.51-7.93, *P* = 0.003) and homozygous (OR = 3.52, 95% CI 1.53-8.10, *P* = 0.003) models (Table [3](#T3){ref-type="table"}).

![Subgroup analysis of the relationship between TAP1 rs1135216 polymorphism and atopic diseases stratified by the ethnicity of study population\
I^2^ and Pheterogeneity for the outcomes of the homozygous comparison in Asians (I^2^ = 0%, *P*~h~=0.995) and Africans (I^2^=0%, *P*~h~=0.532).](oncotarget-09-1553-g004){#F4}

### Publication bias and sensitivity analysis {#s2_1_3}

With the use of Begg\'s funnel plot and quantitative Egger\'s test, publication bias was assessed and no obvious publication bias was found for the association between rs1057141 and atopic diseases risk (Table [2](#T2){ref-type="table"}). Symmetrical funnel plots were obtained in all the genetic models. As for rs1135216, quantitative Egger\'s test of the included studies showed potential publication bias in recessive comparison (*P*~egger~ = 0.016) and homozygote comparison (*P*~egger~ = 0.026) (Table [3](#T3){ref-type="table"}). However, when stratified by ethnicity, such publication bias disappeared in both Asian (recessive: *P*~egger~ = 0.291; homozygous: *P*~egger~ = 0.534) and African (recessive: *P*~egger~ = 0.386; homozygous: *P*~egger~ = 0.375) groups (Table [3](#T3){ref-type="table"}). Result from trim-and-fill analysis, which was to investigate the effect of missing trials, showed "no trimming performed; data unchanged". In addition, sensitivity analysis which evaluated the impact of individual study on overall ORs showed that exclusion of any study made no significant difference (Figure [5](#F5){ref-type="fig"}).

![The impact of individual studies on the overall OR in allele model (G *vs.* A)\
**A.** rs1057141; **B.** rs1135216.](oncotarget-09-1553-g005){#F5}

AD, atopic dermatitis; AR, allergic rhinitis; AA, asthma; OR, odds ratio; CI, confidence interval; NA, not applicable; Bold values are statistically significant (*P* \< 0.05).

DISCUSSION {#s3}
==========

Our study for the first time assessed the relationships between TAP1 rs1057141 and rs1135216 polymorphism and atopic diseases risk through quantitative meta-analysis of the published case-control studies. The results showed that rs1135216 polymorphism might have a significant association with atopic diseases risk.

Allergic diseases are frequent chronic diseases and recognized as a group of immune-mediated disorders \[[@R17]\]. Progress of allergic symptoms could start with atopic dermatitis that could be accompanied with sensitization to aeroallergen during early childhood, followed by asthma and allergic rhinitis during later childhood or adult life \[[@R2], [@R18]\]. Epidemiological studies have demonstrated the atopic diseases have developed as an epidemic disease through the last decades. However, pathogenesis, natural course and the underlying mechanisms of atopic diseases is still unclear. \[[@R19]\]. Etiology of AD includes alterations in skin barrier function, immune dysregulation and exposure to environmental, which could ultimately lead to the classic skin manifestation of AD \[[@R20]\]. Environmental allergens could cross a dysfunctional skin barrier, which will activate immune system and elicit AD symptoms. Antigen presentation, which is required for priming the immunologic response to external antigen is regulated by HLA molecules. HLA are encoded within MHC located on chromosome 6 \[[@R21]\] which hosts hundreds of genes that code for cell-surface antigens and therefore affect immune system function \[[@R21]\].

TAP gene is located within the MHC class II region of chromosome 6 between the HLA-DP and HLA-DQ loci. The TAP protein is critical for the processing and presentation of intracellular antigens \[[@R22]\]. Though most studies on the influences of TAP1 on atopic diseases susceptibility reported consistent findings, contradictory results have been observed from replicating studies of different ethnic populations. TAP1 rs1135216, as a common TAP1 gene polymorphism, is associated with atopic diseases \[[@R5]--[@R7], [@R9], [@R10]\]. Substitution of the 637^th^ amino acid aspartate by glycine in TAP1 protein resulted from the replacement of the 2120^th^ base adenine by guanine in TAP1 rs1135215 compared with that of TAP1 gene seems responsible for the increased atopic diseases risk. From the 10 studies analyzing rs1135216 in exon 10, 4 studies found significant association between rs1135216 and atopic diseases, which was absent from the other 6 studies.

The present meta-analysis systematically evaluated the association between rs1057141 and rs1135216 polymorphisms and atopic diseases susceptibility. Positive association between TAP1 rs1135216 polymorphism and increased atopic diseases risk was observed and patients with the GG genotype may be susceptible to atopic diseases. High heterogeneities were observed in the allele, dominant and heterozygous models. However, when stratified by ethnicity, heterogeneity disappeared in Asians and Africans. Difference between Asians and Africans indicated that rs1135216 polymorphism might be ethnicity-specific. Sub-population analysis revealed association between different genotypes and Africa population. The atopic diseases risk increased significantly in Africa populations using allelic, dominant, recessive, homozygous and heterozygous genetic models. As to rs1057141, increased risk of atopic disease in the allelic, dominant and heterozygous model was found in African population. Additionally, with sensitivity analysis indicating our data stable and robust, our results may assist the establishment of personal therapy in atopic diseases.

A few limitations presented in this meta-analysis should be considered if the data are to be used further. First, different research methods may increase the heterogeneity of these studies. Second, only Asian and African populations are included in the current analysis, and therefore studies on ethnicities such as Caucasians are needed for further investigation. Additionally, the heterogeneity present in some genetic models also posed as limitation of this study. To overcome the limitation present in this study, large-scale studies are required to validate the significance of our conclusions.

In summary, this meta-analysis supported evidence that rs1135216 polymorphism may confer susceptibility to atopic diseases in the overall population and especially among Africans.

MATERIALS AND METHODS {#s4}
=====================

Conduction of meta-analysis was based on the PRISMA guidelines \[[@R23]\].

Search strategy and selection criteria {#s4_1}
--------------------------------------

Databases including PubMed, EMBASE and Web of Science (last updated on July, 2017) were used as the source for identifying published investigations on the relationship between TAP1 polymorphism and atopic risk. Time was not limited for the search of the eligible literature. Keywords used for searching the literature include: 'transporter associated with antigen processing 1','TAP1', 'polymorphism', 'variant', 'genotype', 'allele', 'dermatitis', 'rhinitis', and 'asthma'. Besides, to identify further eligible articles, reference lists of all relevant articles were reviewed manually.

Criteria used for selection of eligible studies include: (1) being a unrelated case-control design study; (2) include investigation of the relationship between TAP1 polymorphisms and atopic dermatitis, allergic rhinitis, and/or asthma; (3) including sufficient data to calculate the pooled ORs with 95% CI \[[@R24]\].

Data extraction and quality assessment {#s4_2}
--------------------------------------

The types of data extracted from the included studies are: first author, publication year, country, ethnicity, genotype methods, the number of cases and controls, distributions of genotypes and alleles in atopic patients and control subjects, and the probability value of HWE in control group. Data extraction was carried out independently by Liu and Chen who also performed study quality assessment. Disagreements were solved by discussion.

Scoring system was established by incorporating traditional epidemiological considerations together with atopic genetic issues recommended by Thakkinstian to assess study quality \[[@R25]\]. Six perspectives were evaluated to assess the study quality: representativeness of samples, ascertainment of samples, genotyping methods, association assessment, response rate and HWE of the control groups ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@R26]\]. The scores were set ranging from 0 (worst) to 15 (best). Any disagreement aroused between the previous mentioned two researchers was adjudicated by a third researcher (Qi). Any study with a quality score of ≤ 4 was considered to be low quality and excluded for further analysis \[[@R27]\].

Statistical analysis {#s4_3}
--------------------

Statistical analysis was performed with StataMP 14 (StataCorp, College Station, TX). Five genetic models including the allelic (G versus A), dominant (AG+GG versus AA), recessive (GG versus AG+AA), homozygous (GG versus AA) and heterozygous (AG versus AA) models were adopted \[[@R28]\]. The relationships between TAP1 gene polymorphism and atopic diseases amongst different models were compared using OR and its corresponding 95% CI. Chi-squared-based Q-test was employed to evaluate the heterogeneity between the individual studies with *P* \< 0.1 considered as significant. In the presence of heterogeneity among individual studies, estimation of pooled OR was conducted utilizing a random-effect model. Otherwise, a fixed-effect model was applied. The pooled OR was determined by Z-test, and OR with *P* \< 0.05 was considered as significant \[[@R29]\]. To confirm the validity of HWE, Genotype distributions in the control subjects were tested with χ^2^ test, and significance was set at *P* \< 0.05. Subgroup analysis by ethnicity and atopic types was performed to investigate possible causes of heterogeneity. Influence of individual study on the overall analysis outcome was assessed by sensitivity analysis, in which the results by stability was tested by excluding each study in sequence to examine their impact on the test of heterogeneity. To determine whether there existed publication bias, Funnel plots, Begg\'s test and Egger\'s test were applied. In the case of presence of publication bias, the trim and fill approach was applied to adjust the meta-analysis results by imputing data from presumed missing studies \[[@R30]\].

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================
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